Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | PLIN1 | O60240 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | PLIN5 | Q00G26 | 2/20 | 0.59 |
| ▸ | ABHD5 | Q8WTS1 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | TNKS | O95271 | 1/20 | 0.59 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5231718 | 1.00 | TDP1 (0.61) | TDP1GLAALDH1A1HDAC3HDAC4 | |
| Chalcone SCHEMBL7008520 | 0.89 | CYP1B1 (0.73) | TDP1ALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL2622484 | 0.89 | HDAC2 (0.59) | TDP1GLAALDH1A1HDAC3HDAC4 | |
| SCHEMBL5598797 | 0.88 | TDP1 (0.61) | TDP1GLAALDH1A1HDAC3HDAC4 | |
| SCHEMBL5598795 | 0.88 | TDP1 (0.61) | TDP1GLAALDH1A1HDAC3HDAC4 | |
| SCHEMBL13689262 | 0.86 | HDAC3 (0.58) | TDP1GLAALDH1A1HDAC3HDAC4 | |
| SCHEMBL27727863 | 0.86 | TDP1 (0.59) | TDP1GLAALDH1A1HDAC3HDAC4 | |
| SCHEMBL8349461 | 0.85 | HDAC3 (0.56) | TDP1GLAALDH1A1HDAC3HDAC4 | |
| SCHEMBL3308815 | 0.84 | TDP1 (0.57) | TDP1GLAALDH1A1HDAC3HDAC4 | |
| SCHEMBL3308818 | 0.84 | TDP1 (0.57) | TDP1GLAALDH1A1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018002-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | MEDICON PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | MEDICON PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| WO-2023028350-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20220396583-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| US-11384094-B2 | Chiral auxiliaries and uses thereof | Greatrex, Ben (AU) | 2022-07-12 | — | — | US | disclosed |
| US-6201123-B1 | FOR ASYMMETRIC EPOXIDATION OF ENONES; GIVES EPOXIDES HAVING AN ENHANCED OPTICAL PURITY | TECHNO POLYMER CO., LTD. (JP) | 2001-03-13 | — | — | US | disclosed |
| US-5072023-A | Reacting lactone with ester anion to form cyclohexenone ester; oxidizing or dehydrogenating the intermediate | E. R. SQUIBB & SONS, INC. (US) | 1991-12-10 | — | — | US | disclosed |
| EP-0442495-A1 | Process for preparing highly substituted phenyls | E.R. SQUIBB & SONS, INC. (US) | 1991-08-21 | — | — | EP | disclosed |
| EP-0004624-B1 | CHROMANON DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICINES AND GROWTH-PROMOTING AGENTS | BAYER AG (DE) | 1982-02-24 | — | — | EP | disclosed |
| US-RE30812-E | ANTIARRHTHMIA AGENTS | MEAD JOHNSON & COMPANY (US) | 1981-12-01 | — | — | US | disclosed |
| US-4261988-A | ANTICHOLESTEROL AGENTS USED IN ANIMAL HUSBANDRY | BAYER AKTIENGESELLSCHAFT (DE) | 1981-04-14 | — | — | US | disclosed |
| EP-0004624-A2 | Chromanon derivatives, process for their preparation, and their use as medicines and growth-promoting agents | BAYER AG (DE) | 1979-10-17 | — | — | EP | disclosed |
| US-4000143-A | ANTIARRHYTHMIC AND ANTISEROTONIN AGENTS | MEAD JOHNSON & COMPANY (US) | 1976-12-28 | — | — | US | disclosed |
| US-3989708-A | HYPOTENSIVE, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-02 | — | — | US | disclosed |
| US-3931195-A | ANTIARRHYTHMIA, ANTISEROTONIN | MEAD JOHNSON & COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018002-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | TDP1 1193/4885GLA 1942/4885ALDH1A1 1767/4885 |
| US-11384094-B2 | Chiral auxiliaries and uses thereof | PIN1, CRY1, PIN4 | TDP1 3804/4885GLA 1580/4885ALDH1A1 703/4885 |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | VEGFA, HPGDS, ALOX5 | TDP1 749/4885GLA 95/4885ALDH1A1 921/4885 |
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | VEGFA, HPGDS, ALOX5 | TDP1 749/4885GLA 95/4885ALDH1A1 921/4885 |
| US-20220396583-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | TLR2, TLR4, TLR3 | TDP1 1563/4885GLA 2244/4885ALDH1A1 4464/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | TDP1 1942/4885GLA 1297/4885ALDH1A1 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.